Changchun Qijian is a wholly-owned subsidiary of China Biotechnology Co., Ltd., a subsidiary of China Pharmaceutical Group, a central enterprise directly under the State-owned Assets Supervision and Administration Commission, and Beijing Bio is a secondary subsidiary of China Biotechnology Co., Ltd., a subsidiary of China Pharmaceutical Group.
Beijing Institute of Biological Products Co., Ltd. is a wholly state-owned biotechnology enterprise with a long history, integrating production, research and development, education and sales.
Operating products
Changchun Qijian's main product is live attenuated varicella vaccine, which is the first domestic enterprise to produce and export live attenuated varicella vaccine, and also the largest varicella vaccine manufacturer on the market at present.
The main biological products in Beijing are virus vaccines and recombinant products, and it is the first interferon pilot base and the first industrialized production base of hepatitis B genetic engineering vaccine in China.